ENDRA Life Sciences Q3 net loss narrows on digital asset gains

By Reuters News


Overview

  • US thermoacoustic imaging firm's Q3 net loss narrowed yr/yr, aided by digital asset gains

  • Company's operating expenses rose due to higher merger-related professional fees

  • ENDRA focused on completing proposed merger with Noble Africa and $50 mln private placement


Outlook

  • Company remains focused on completing proposed merger with Noble Africa and related transactions

  • Completion of the merger is subject to customary closing conditions, including stockholder approvals

  • Company did not provide specific financial guidance for future quarters or the full year


Result Drivers

  • MERGER-RELATED COSTS - Higher professional fees and costs tied to the proposed merger with Noble Africa increased operating expenses

  • DIGITAL ASSET GAINS - Net loss narrowed yr/yr due to realized and unrealized gains on digital assets

  • REDUCED R&D SPENDING - Research and development expenses declined compared to the prior-year period


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$1.50 mln

Q3 Operating Expenses

$1.70 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $25.00, about 466.9% above its November 13 closing price of $4.41


Reuters Recommended Reads

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall

  • Nov 16 - Prelude Therapeutics Q3 net loss narrows as expenses fall

  • Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.